Article
Allele-dependent variation in the relative cellular potency of distinct EGFR inhibitors.
Cancer biology & therapy - 1 May 2007
Yuza Yuki, Glatt Karen A, Jiang Jingrui, Greulich Heidi, Minami Yuko, Woo Michele S, Shimamura Takeshi, Shapiro Geoffrey, Lee Jeffrey C, Ji Hongbin, Feng Whei, Chen Tzu-Hsiu, Yanagisawa Haruhiko, Wong Kwok-Kin, Meyerson Matthew
Abstract excerpt
Targeted cancer therapies impede cancer cell growth by inhibiting the function of activated oncogene products. Patients with non-small cell lung cancer and somatic mutations of EGFR can have a dramatic response to treatment with erlotinib and gefitinib; different somatic mutations are associated with different times to progression and survival. In this study, the relative and absolute potencies of two distinct...
Topics
- Alleles
- Amino Acid Substitution
- Animals
- Cell Survival
- Cells, Cultured
- DNA Primers
- ErbB Receptors
- Erlotinib Hydrochloride
- Humans
- Lung Neoplasms
- Mice
- Peptide Fragments
- Phosphorylation